title: Advances in immunotherapy of chronic myeloid leukemia CML.
abstract: Tyrosine kinase inhibitors induce sustained disease remissions in chronic myeloid leukemia by exploiting the addiction of this type of leukemia to the activity of the fusion oncogene BCR-ABL. However, these agents fail to eradicate CML stem cells which are ultimately responsible for disease relapses upon treatment discontinuation. Evidence that the immune system can effectively reject CML stem cells potentially leading to patient cure is provided by the experience with patients receiving allogeneic bone marrow transplantations. Compelling evidence indicates that more modern, antigen-specific immunotherapeutic approaches are also feasible and hold strong potential to be clinically effective. Amongst these, particularly promising is the use of autologous dendritic cells pulsed with antigens or direct application of in vitro transcribed RNA encoding for leukemia-associated antigens, since this approach allows to circumvent HLA-restriction of the leukemia-associated T cell epitopes that have been eventually identified. Combining these strategies with monoclonal antibodies, such as anti-CTLA-4 or anti-PD-1, may help to obtain even stronger immune responses and better clinical results. This narrative review addresses this topic by focusing in particular on the cell-based immunotherapeutic strategies for CML and on the issue of the leukemia-associated antigens to be selected for targeting.
authors.affiliation: Medizinische Klinik III, Hämatologie/Onkologie; Wilhelmstr. 35-37, 53111 Bonn in Sigmund-Freud- Str. 25, 53105 Bonn, Germany. Peter.Brossart@ukb.uni-bonn.de.
authors.forename: Stefanie Andrea Erika
authors.initials: SA
authors.lastname: Held
authors.forename: Annkristin
authors.initials: A
authors.lastname: Heine
authors.forename: Karin Tina
authors.initials: KT
authors.lastname: Mayer
authors.forename: Mario
authors.initials: M
authors.lastname: Kapelle
authors.forename: Dominik Georg Friedrich
authors.initials: DG
authors.lastname: Wolf
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm